ArticleGels (Basel, Switzerland)2022
Preparation of Chitosan/Recombinant Human Collagen-Based Photo-Responsive Bioinks for 3D Bioprinting.
Article in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Synthesis and Characterization of a Marine Collagen-Chitosan/HA-SiOGels (Basel, Switzerland) · 2026Article
- Advances in Cryopreservation Strategies for 3D Biofabricated Constructs: From Hydrogels to Bioprinted Tissues.International journal of molecular sciences · 2025Review
- Unlocking 3D printing technology for microalgal production and application.Advanced biotechnology · 2024Review
- Review
- Light-based 3D bioprinting technology applied to repair and regeneration of different tissues: A rational proposal for biomedical applications.Materials today. Bio · 2024Review
- Hydrogel-Based 3D Bioprinting Technology for Articular Cartilage Regenerative Engineering.Gels (Basel, Switzerland) · 2024Review
- Xeno-Free 3D Bioprinted Liver Model for Hepatotoxicity Assessment.International journal of molecular sciences · 2024Article
- Tissue engineering applications of recombinant human collagen: a review of recent progress.Frontiers in bioengineering and biotechnology · 2024Review
- Marine Collagen-Based Bioink for 3D Bioprinting of a Bilayered Skin Model.Pharmaceutics · 2023Article
- Bioinks adapted forRSC advances · 2023Review
- Natural Materials for 3D Printing and Their Applications.Gels (Basel, Switzerland) · 2022Review
- Obtaining and Characterizing Composite Biomaterials of Animal Resources with Potential Applications in Regenerative Medicine.Polymers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Collagen and chitosan are frequently used natural biomaterials in tissue engineering. However, most collagen is derived from animal tissue, with inconsistent quality and pathogen transmittance risks. In this context, we aimed to use a reliable Type-III recombinant human collagen (RHC) as an alternative biomaterial together with chitosan to develop novel photo-responsive bioinks for three-dimensional (3D) bioprinting. RHC was modified with methacrylic anhydride to obtain the RHC methacryloyl (RHCMA) and mixed with acidified chitosan (CS) to form composites CS-RHCMA. The characterizations demonstrated that the mechanical properties and the degradation of the bioinks were tunable by introducing the CS. The printabilities improved by adding CS to RHCMA, and various structures were constructed via extrusion-based 3D printing successfully. Moreover, in vitro tests confirmed that these CS-RHCMA bioinks were biocompatible as human umbilical vein endothelial cells (HUVECs) were sustained within the constructs post-printing. The results from the current study illustrated a well-established bioinks system with the potential to construct different tissues through 3D bioprinting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.